Analytical quality control in neonatal screening

Tuuminen, Tamara; Käpyaho, Kirsti; Rakkolainen, Airi; Weber, T.

doi:10.1016/0009-9120(94)00054-y

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differentials in the uptake of disorders into screening programmes are suggestive of discrepancies between screening criteria and a lack of international standardization (Tuuminen et al 1994). The development of screening programmes and the differences that have evolved are the consequence of context-specific interpretations of and amendments to screening criteria (Clague and Thomas 2002; Padilla et al 2010).…”

Section: Newborn Metabolic Screening Programme: a Short Historymentioning

confidence: 99%

“…Instead, these decisions are made by and directly impact upon the baby’s parents, an additional complication that needs special consideration. Despite this, there has been no international consensus on an appropriate set of criteria for the newborn context (Clague and Thomas 2002; Padilla et al 2010; Tuuminen et al 1994). In order to explore how these difficulties are managed in practice, we now turn to a specific case study: New Zealand.…”

Section: Screening Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Forman¹,

Coyle²,

Levy-Fisch³

et al. 2012

J Community Genet

View full text Add to dashboard Cite

Newborn metabolic screening is the most widespread application of screening technology and provides the most comprehensive application of genetics in health services, where the Guthrie blood spot cards allow screening for metabolic diseases in close to 100 % of all newborn babies. Despite over 40 years of use and significant benefits to well in excess of 100,000 children worldwide, there is remarkably little consensus in what conditions should be screened for and response to new advances in medicine relating to programme expansion. In this article, the international criteria for newborn metabolic screening are considered, and we propose that these criteria are poorly developed in relation to the baby, its family and society as a whole. Additionally, the ethical issues that should inform the application of screening criteria are often not developed to a level where a consensus might easily be achieved. We also consider that when family interests are factored in to the decision-making process, they have a significant influence in determining the list of diseases in the panel, with countries or states incorporating family and societal values being the most responsive. Based on our analysis, we propose that decision criteria for metabolic screening in the newborn period should be adapted to specifically include parent and family interests, community values, patients’ rights, duties of government and healthcare providers, and ethical arguments for action in the face of uncertainty.

show abstract

Section: Newborn Metabolic Screening Programme: a Short Historymentioning

confidence: 99%

Section: Screening Criteriamentioning

confidence: 99%

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Forman¹,

Coyle²,

Levy-Fisch³

et al. 2012

J Community Genet

View full text Add to dashboard Cite

show abstract

“…Regional standardization has been more successful (Watanabe et al 2006). The need for international guidelines for newborn screening methods assessment and comparison, with an emphasis on clinical relevance, has been argued (Tuuminen et al 1994).…”

Section: Laboratory Qualitymentioning

confidence: 99%

Quality performance of newborn screening systems: Strategies for improvement

Webster¹

2007

J of Inher Metab Disea

View full text Add to dashboard Cite

Newborn metabolic screening is a public health activity with the potential to realize significant health gains for infants affected with a range of congenital conditions. Many of these are inborn errors of metabolism. The activities required to achieve the gains are diverse and carried out by a number of organizations, by families and by many health care professionals. Laboratories have the best-developed quality strategies, which include quality assurance programmes, guidelines, protocols and standards. Two-tier testing and use of multiple markers improve sensitivity and specificity. There are international initiatives to harmonize assay materials and definitions to allow better benchmarking between programmes. Outside the laboratory, standards, education and protocols improve the quality of specimen collection, diagnosis and treatment, which together produce the health gains.

show abstract

The need for standardized bloodspot TSH-calibrators in congenital hypothyroidism screening

Elvers

Loeber

1996

Early Human Development

View full text Add to dashboard Cite

Analytical quality control in neonatal screening

Cited by 3 publications

References 19 publications

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Quality performance of newborn screening systems: Strategies for improvement

The need for standardized bloodspot TSH-calibrators in congenital hypothyroidism screening

Contact Info

Product

Resources

About